Skip to main content

Acne Rosacea

Dermatology
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.

$0.292B marketMature→ Stable30 products15 companies

Key Trends

  • HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
  • Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
  • Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market

Career Verdict

Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING
#2VTAMAGrowing
$19M
Merck & Co.·PEAK13.5yr
#3ORACEADeclining
$4M
Galderma·LOE_APPROACHING1.6yr

Drug Class Breakdown

Unknown Mechanism (predominantly HUMIRA)
$258M(88%)

Patent cliff looming

Aryl Hydrocarbon Receptor Agonists
$19M(6%)

Emerging innovation

Retinoids and Derivatives
$3M(1%)

Mature segment

Other Mechanisms
$12M(4%)

Niche applications

Career Outlook

Stable

Dermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.

Breaking In

Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.

For Experienced Professionals

Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.

In-Demand Skills

Health Economics & Outcomes Research (HEOR)Dermatology Clinical KnowledgeSales Strategy & Account ManagementDigital Health / Telemedicine IntegrationMedical Writing for Topicals & Systemics

Best For

Regional Sales ManagerMedical Science Liaison (MSL)Product Manager (Post-Launch)Health Economics ManagerRegulatory Affairs Specialist

Hiring Landscape

$85K-$386K

Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.

173
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

53Growing
46Growing
14Stable

By Department

Commercial(51%)
$188K
Medical Affairs(24%)
$386K
Research & Development(5%)

Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
Azelaic acid 15%Phase 41 trial
Active Trials
NCT02147691Completed22Est. Feb 2015
Dermata Therapeutics
2 programs
2
DMT210 Topical Gel 5%Phase 21 trial
Topical PowderPhase 21 trial
Active Trials
NCT03003104Completed107Est. Aug 2017
NCT05108025Unknown180Est. Dec 2022
Accuitis
AccuitisGA - Alpharetta
1 program
1
ACCU-D1Phase 21 trial
Active Trials
NCT03064438Completed40Est. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerAzelaic acid 15%
Dermata TherapeuticsTopical Powder
AccuitisACCU-D1
Dermata TherapeuticsDMT210 Topical Gel 5%

Clinical Trials (4)

Total enrollment: 349 patients across 4 trials

NCT02147691BayerAzelaic acid 15%

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

Start: May 2014Est. completion: Feb 201522 patients
Phase 4Completed

DMT310-005 Topical in the Treatment of Acne Rosacea

Start: Nov 2021Est. completion: Dec 2022180 patients
Phase 2Unknown

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Start: Nov 2017Est. completion: Jun 201840 patients
Phase 2Completed
NCT03003104Dermata TherapeuticsDMT210 Topical Gel 5%

DMT210 Topical Gel in the Treatment of Acne Rosacea

Start: Jan 2017Est. completion: Aug 2017107 patients
Phase 2Completed

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.